Neoadjuvant Only

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if incorporating both neoadjuvant and adjuvant therapy through a perioperative approach offers greater benefit. Discussion will review emerging clinical trial data, survival outcomes, and toxicity considerations. Participants will explore how these approaches may be optimally applied in contemporary resectable lung cancer care. The speaker will review clinical trial data supporting preoperative systemic approaches, including chemotherapy and immunotherapy, and their impact on pathologic response and surgical outcomes. The discussion will address patient selection, timing of surgery, and safety considerations, and revisit the benefits and limitations of neoadjuvant strategies in resectable lung cancer.